-DOCSTART- -X- O
ABT-263 -X- _ B-Intervention
and -X- _ O
its -X- _ O
structural -X- _ O
analogues -X- _ O
ABT-199 -X- _ O
and -X- _ O
ABT-737 -X- _ O
inhibit -X- _ O
B-cell -X- _ O
lymphoma -X- _ O
2 -X- _ O
( -X- _ O
Bcl-2 -X- _ O
) -X- _ O
, -X- _ O
BCL2L1 -X- _ O
long -X- _ O
isoform -X- _ O
( -X- _ O
Bcl-xL -X- _ O
) -X- _ O
and -X- _ O
BCL2L2 -X- _ O
( -X- _ O
Bcl-w -X- _ O
) -X- _ O
proteins -X- _ O
and -X- _ O
promote -X- _ O
cancer -X- _ O
cell -X- _ O
death. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
at -X- _ O
non-cytotoxic -X- _ O
concentrations -X- _ O
, -X- _ O
these -X- _ O
small -X- _ O
molecules -X- _ O
accelerate -X- _ B-Outcome
the -X- _ I-Outcome
deaths -X- _ I-Outcome
of -X- _ I-Outcome
non-cancerous -X- _ I-Outcome
cells -X- _ I-Outcome
infected -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
virus -X- _ I-Outcome
( -X- _ I-Outcome
IAV -X- _ I-Outcome
) -X- _ I-Outcome
or -X- _ I-Outcome
other -X- _ I-Outcome
viruses. -X- _ I-Outcome
In -X- _ O
particular -X- _ O
, -X- _ O
we -X- _ O
demonstrate -X- _ O
that -X- _ O
ABT-263 -X- _ B-Intervention
altered -X- _ B-Outcome
Bcl-xL -X- _ I-Outcome
interactions -X- _ I-Outcome
with -X- _ I-Outcome
Bcl-2 -X- _ I-Outcome
antagonist -X- _ I-Outcome
of -X- _ I-Outcome
cell -X- _ I-Outcome
death -X- _ I-Outcome
( -X- _ I-Outcome
Bad -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
Bcl-2-associated -X- _ I-Outcome
X -X- _ I-Outcome
protein -X- _ I-Outcome
( -X- _ I-Outcome
Bax -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
uveal -X- _ I-Outcome
autoantigen -X- _ I-Outcome
with -X- _ I-Outcome
coiled-coil -X- _ I-Outcome
domains -X- _ I-Outcome
and -X- _ I-Outcome
ankyrin -X- _ I-Outcome
repeats -X- _ I-Outcome
protein -X- _ I-Outcome
( -X- _ I-Outcome
UACA -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
ABT-263 -X- _ I-Outcome
thereby -X- _ I-Outcome
activated -X- _ I-Outcome
the -X- _ I-Outcome
caspase-9-mediated -X- _ I-Outcome
mitochondria-initiated -X- _ I-Outcome
apoptosis -X- _ I-Outcome
pathway -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
, -X- _ I-Outcome
together -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
IAV-initiated -X- _ I-Outcome
caspase-8-mediated -X- _ I-Outcome
apoptosis -X- _ I-Outcome
pathway -X- _ I-Outcome
, -X- _ I-Outcome
triggered -X- _ I-Outcome
the -X- _ I-Outcome
deaths -X- _ I-Outcome
of -X- _ I-Outcome
IAV-infected -X- _ I-Outcome
cells. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
also -X- _ O
indicate -X- _ O
that -X- _ O
Bcl-xL -X- _ B-Outcome
, -X- _ I-Outcome
Bcl-2 -X- _ I-Outcome
and -X- _ I-Outcome
Bcl-w -X- _ I-Outcome
interact -X- _ I-Outcome
with -X- _ I-Outcome
pattern -X- _ I-Outcome
recognition -X- _ I-Outcome
receptors -X- _ I-Outcome
( -X- _ I-Outcome
PRRs -X- _ I-Outcome
) -X- _ I-Outcome
that -X- _ I-Outcome
sense -X- _ I-Outcome
virus -X- _ I-Outcome
constituents -X- _ I-Outcome
to -X- _ I-Outcome
regulate -X- _ I-Outcome
cellular -X- _ I-Outcome
apoptosis. -X- _ I-Outcome
Importantly -X- _ O
, -X- _ O
premature -X- _ B-Outcome
killing -X- _ I-Outcome
of -X- _ I-Outcome
IAV-infected -X- _ I-Outcome
cells -X- _ I-Outcome
by -X- _ I-Outcome
ABT-263 -X- _ I-Outcome
attenuated -X- _ I-Outcome
the -X- _ I-Outcome
production -X- _ I-Outcome
of -X- _ I-Outcome
key -X- _ I-Outcome
pro-inflammatory -X- _ I-Outcome
and -X- _ I-Outcome
antiviral -X- _ I-Outcome
cytokines. -X- _ I-Outcome
The -X- _ I-Outcome
imbalance -X- _ I-Outcome
in -X- _ I-Outcome
cytokine -X- _ I-Outcome
production -X- _ I-Outcome
was -X- _ I-Outcome
also -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
ABT-263-treated -X- _ I-Outcome
IAV-infected -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
an -X- _ I-Outcome
inability -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
immune -X- _ I-Outcome
system -X- _ I-Outcome
to -X- _ I-Outcome
clear -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
and -X- _ I-Outcome
eventually -X- _ I-Outcome
lowered -X- _ I-Outcome
the -X- _ I-Outcome
survival -X- _ I-Outcome
rates -X- _ I-Outcome
of -X- _ I-Outcome
infected -X- _ I-Outcome
animals. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
the -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
chemical -X- _ B-Outcome
inhibition -X- _ I-Outcome
of -X- _ I-Outcome
Bcl-xL -X- _ I-Outcome
, -X- _ I-Outcome
Bcl-2 -X- _ I-Outcome
and -X- _ I-Outcome
Bcl-w -X- _ I-Outcome
could -X- _ I-Outcome
potentially -X- _ I-Outcome
be -X- _ I-Outcome
hazardous -X- _ I-Outcome
for -X- _ I-Outcome
cancer -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
. -X- _ O

